Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.35 |
| ▸ | AURKA | O14965 | 4/20 | 0.35 |
| ▸ | NAMPT | P43490 | 8/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10065730 | 0.93 | CNR2 (0.35) | NAMPTCNR2 | |
| SCHEMBL9892776 | 0.93 | AURKA (0.37) | AURKANAMPTCNR2ALOX15HDAC3 | |
| SCHEMBL2808594 | 0.92 | OPRL1 (0.36) | OPRL1AURKANAMPTCNR2MAPK3 | |
| SCHEMBL10071822 | 0.91 | EPHX2 (0.34) | NAMPT | |
| SCHEMBL2805106 | 0.89 | AURKA (0.35) | OPRL1AURKACNR2MAPK3MAPK1 | |
| SCHEMBL15460053 | 0.89 | OPRL1 (0.34) | OPRL1AURKACNR2MAPK3MAPK1 | |
| SCHEMBL16270496 | 0.89 | NAMPT (0.33) | OPRL1NAMPT | |
| SCHEMBL15460097 | 0.88 | ALOX15 (0.36) | OPRL1AURKACNR2MAPK3MAPK1 | |
| SCHEMBL2808301 | 0.88 | OPRL1 (0.37) | OPRL1CNR2MAPK3MAPK1HDAC3 | |
| SCHEMBL2809085 | 0.87 | OPRL1 (0.38) | OPRL1CNR2MAPK3MAPK1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606043-B1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20140038977-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| WO-2012022794-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038977-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BDKRB1, BDKRB2, HRH2 | OPRL1 141/4885AURKA 2115/4885NAMPT 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.